Furthermore, in a study comparing the efficacy of denosumab, a monoclonal antibody targeting RANKL, and romosozumab in patients with RA undergoing chronic treatment with glucocorticoids, a similar improvement in disease activity between the two groups was observed [40]. Here, TNFSF11 is linked to rheumatoid arthritis.